Cubist Pharmaceuticals Inc Fourth Quarter Earnings Sneak Peek

Cubist Pharmaceuticals Inc (NASDAQ:CBST) will unveil its latest earnings tomorrow, Wednesday, January 23, 2013. Cubist Pharmaceuticals is focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.

Cubist Pharmaceuticals Inc Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for net income of 48 cents per share, a rise of more than fourfold from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from 45 cents. Between one and three months ago, the average estimate was unchanged. It has risen during the last month. Analysts are projecting profit to rise by 44.5% versus last year to $1.98.

Past Earnings Performance: Last quarter, the company reported profit of 68 cents per share versus a mean estimate of net income of. The company has beaten estimates for the past three quarters.

Start 2013 better than ever by saving time and making money with your Limited Time Offer for our highly-acclaimed Stock Picker Newsletter. Click here for our fresh Feature Stock Pick now!

A Look Back: In the third quarter, profit rose 66.4% to $40.3 million (55 cents a share) from $24.2 million (33 cents a share) the year earlier, exceeding analyst expectations. Revenue rose 18.1% to $238.2 million from $201.7 million.

Here’s how Cubist Pharmaceuticals Inc traded following its last earnings report 3 months ago and leading up to its upcoming earnings report this week:

CBST

Balance Sheet Analysis: The company’s current ratio of assets to liabilities came in at 3.49 last quarter. Having a ratio above 2:1 is usually considered a good indicator of a company’s liquidity and ability to meet creditor demands.

Wall St. Revenue Expectations: Analysts are projecting a rise of 15.7% in revenue from the year-earlier quarter to $246.4 million.

Key Stats:

With double-digit revenue growth the past four quarters, this earnings release is a chance to keep that positive trend going. The company has averaged year-over-year revenue growth of 27.6% over the last four quarters.

Analyst Ratings: There are 10 out of 16 analysts surveyed (62.5%) rating Cubist Pharmaceuticals a buy.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute — click here and get our CHEAT SHEET stock picks now.

(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)